| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
RNA polymerase in nontuberculous mycobacteria (NTM).
|
|---|---|
| ln Vitro |
MMV688845 is able to impede M. abscessus ATCC 19977 has a MIC value of 9.3 μM in a dose-dependent manner.
MMV688845 dose-dependently inhibits the growth of M. abscessus (ATCC 19977) with a minimum inhibitory concentration (MIC) of 9.3 uM. |
| ln Vivo |
In vivo activity has been demonstrated in mouse models of tuberculosis, showing efficacy against Mycobacterium tuberculosis.
|
| Enzyme Assay |
Not fully detailed in available sources; typically, RNA polymerase binding assays are performed using purified bacterial RNA polymerase enzyme with radiolabeled substrates to measure transcription inhibition under cell-free conditions.
|
| Cell Assay |
Not fully detailed in available sources; typically, mycobacterial growth inhibition assays are performed in 7H9 broth medium using the microplate Alamar Blue assay (MABA) method, with bacterial cultures incubated with serial compound dilutions for 3-7 days followed by fluorescence reading to determine MIC values.
|
| Animal Protocol |
Typically, mouse models of tuberculosis infection are used, where mice are infected with Mycobacterium tuberculosis via aerosol route, then treated daily with oral or intraperitoneal administration of MMV688845 for several weeks; endpoints include lung bacterial load and survival rate.
|
| ADME/Pharmacokinetics |
Standard PK parameters have not been fully detailed in available sources; based on its chemical properties, permeability and moderate bioavailability are expected; further ADME studies are needed to determine its half-life, plasma clearance, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Toxicological profile not fully described; as an experimental compound not yet in clinical trials, safety assessments (including acute and repeat-dose toxicity in animal models) are still under investigation; currently used only for research purposes.
|
| References |
[1]. Jinsun Jeong, et al. Pathogen Box screening for hit identification against Mycobacterium abscessus. PLoS One. 2018 Apr 26;13(4):e0195595.
|
| Additional Infomation |
MMV688845 ((R)-GSK1729177A) is an experimental RNA polymerase inhibitor developed as a potential treatment for tuberculosis and nontuberculous mycobacterial infections; it is still in preclinical research stage and has not been approved for clinical use; no phase I/II/III clinical trials have been registered to date.
|
| Molecular Formula |
C24H25N3O3S
|
|---|---|
| Molecular Weight |
435.53860449791
|
| Exact Mass |
435.16
|
| Elemental Analysis |
C, 66.19; H, 5.79; N, 9.65; O, 11.02; S, 7.36
|
| CAS # |
2208962-35-8
|
| PubChem CID |
122196547
|
| Appearance |
Solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1(C(N[C@H](CC2=CC=CC=C2)C(NC2=CC=CC=C2N2CCOCC2)=O)=O)SC=CC=1
|
| InChi Key |
YZLODHPDCSNHTP-HXUWFJFHSA-N
|
| InChi Code |
InChI=1S/C24H25N3O3S/c28-23(25-19-9-4-5-10-21(19)27-12-14-30-15-13-27)20(17-18-7-2-1-3-8-18)26-24(29)22-11-6-16-31-22/h1-11,16,20H,12-15,17H2,(H,25,28)(H,26,29)/t20-/m1/s1
|
| Chemical Name |
N-[(2R)-1-(2-morpholin-4-ylanilino)-1-oxo-3-phenylpropan-2-yl]thiophene-2-carboxamide
|
| Synonyms |
MMV688845; MMV-688845; MMV 688845
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2960 mL | 11.4800 mL | 22.9600 mL | |
| 5 mM | 0.4592 mL | 2.2960 mL | 4.5920 mL | |
| 10 mM | 0.2296 mL | 1.1480 mL | 2.2960 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
